Johnson & Johnson (NYSE:JNJ) Shares Sold by ETF Portfolio Partners Inc.

ETF Portfolio Partners Inc. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,661 shares of the company’s stock after selling 114 shares during the quarter. ETF Portfolio Partners Inc.’s holdings in Johnson & Johnson were worth $275,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. MTM Investment Management LLC increased its position in shares of Johnson & Johnson by 0.5% in the first quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock worth $1,749,000 after acquiring an additional 61 shares in the last quarter. OneAscent Financial Services LLC increased its position in shares of Johnson & Johnson by 3.3% in the first quarter. OneAscent Financial Services LLC now owns 1,986 shares of the company’s stock worth $308,000 after acquiring an additional 63 shares in the last quarter. Beech Hill Advisors Inc. increased its position in shares of Johnson & Johnson by 0.3% in the second quarter. Beech Hill Advisors Inc. now owns 23,595 shares of the company’s stock worth $3,906,000 after acquiring an additional 63 shares in the last quarter. FIDELIS iM LLC increased its position in shares of Johnson & Johnson by 3.1% in the fourth quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock worth $374,000 after acquiring an additional 64 shares in the last quarter. Finally, Well Done LLC increased its position in shares of Johnson & Johnson by 0.4% in the first quarter. Well Done LLC now owns 15,584 shares of the company’s stock worth $2,415,000 after acquiring an additional 64 shares in the last quarter. 68.40% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent analyst reports. Stifel Nicolaus raised their price target on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. JPMorgan Chase & Co. increased their price objective on shares of Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday. Atlantic Securities increased their price objective on shares of Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a research note on Friday, August 4th. Finally, HSBC initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, September 6th. They set a “hold” rating and a $175.00 price objective on the stock. Nine research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $170.65.

Johnson & Johnson Trading Up 0.6 %

Shares of NYSE:JNJ opened at $162.41 on Tuesday. The company has a market cap of $422.10 billion, a PE ratio of 32.88, a P/E/G ratio of 3.26 and a beta of 0.54. The company’s 50-day moving average price is $166.21 and its 200 day moving average price is $161.83. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $181.04. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.62 by $0.18. The firm had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. Johnson & Johnson’s quarterly revenue was up 6.3% on a year-over-year basis. During the same quarter last year, the company earned $2.59 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.03 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 7th. Shareholders of record on Monday, August 28th were paid a dividend of $1.19 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $4.76 annualized dividend and a yield of 2.93%. Johnson & Johnson’s payout ratio is 96.36%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares in the company, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.